Literature DB >> 1723001

An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen.

S Mishiro1, K Takeda, Y Hoshi, A Yoshikawa, T Gotanda, Y Itoh.   

Abstract

GOR, an epitope borne by the amino acid sequence, GRRGQKAKSNPNRPL, is recognized by anti-GOR antibodies specifically found in patients with non-A, non-B hepatitis (NANBH). The epitope is not coded for by the hepatitis C virus (HCV), the presumed causative agent for NANBH, but by a single copy gene of the host. Anti-GOR antibodies, distinct from anti-HCV (c100-3) antibodies, were revealed to have dual specificities; they target both the presumed core gene product of HCV and a host component. This cross recognition is probably derived from homologous regions between the GOR epitope and a viral epitope on the core protein in HCV. It is therefore suggested that anti-GOR is an autoantibody induced by HCV infection. This may explain the autoimmune disease like aspect of NANBH pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723001     DOI: 10.3109/08916939109001900

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  11 in total

1.  The GOR gene product cannot cross-react with hepatitis C virus in humans.

Authors:  R Koike; T Iizuka; T Watanabe; N Miyasaka
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Chronic hepatitis C associated with anti-liver/kidney microsome-1 antibody is not a subgroup of autoimmune hepatitis.

Authors:  H Miyakawa; E Kitazawa; K Abe; N Kawaguchi; H Fuzikawa; K Kikuchi; M Kako; T Komatsu; N Hayashi; K Kiyosawa
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

3.  Immune response to GOR, a marker for non-A, non-B hepatitis and its correlation with hepatitis C virus infection.

Authors:  S U Mehta; S Mishiro; K Sekiguchi; T Leung; G J Dawson; L M Pendy; D A Peterson; S G Devare
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

4.  Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA.

Authors:  R Seelig; M Renz; G Bünger; H Schröter; H P Seelig
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

Review 5.  Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C.

Authors:  Ayssa A Self; Phyllis T Losikoff; Stephen H Gregory
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

6.  Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein.

Authors:  Z X Zhang; M Chen; K Wallhagen; J Trojnar; L O Magnius; B Wahren; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

7.  Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies.

Authors:  Juan A Quiroga; Inmaculada Castillo; Javier Bartolomé; Vicente Carreño
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

8.  Serological reactivity and viral genotypes in hepatitis C virus infection.

Authors:  F Maggi; M L Vatteroni; M Pistello; C M Avio; N Cecconi; F Panicucci; M Bendinelli
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

9.  Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.

Authors:  Masato Nakamura; Tatsuo Kanda; Tatsuo Miyamura; Shuang Wu; Shingo Nakamoto; Osamu Yokosuka
Journal:  Int J Med Sci       Date:  2013-06-15       Impact factor: 3.738

Review 10.  Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C.

Authors:  Phyllis T Losikoff; Alyssa A Self; Stephen H Gregory
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.